Scott Gottlieb criticizes CMS in feud over Aduhelm coverage, calls out their lack of expertise

Former FDA commissioner and current Pfizer board member Scott Gottlieb went on the offensive against CMS this morning — citing the agency’s “flawed decision making” and how the agency’s decision on Aduhelm is putting not just Alzheimer’s drug research in limbo but potentially setting a negative precedent for accelerated approvals.